Silencing tau to treat early Alzheimer’s disease

n antisense oligonucleotide therapy substantially reduced tau expression in a phase 1b trial; whether this translates to clinical improvement remains to be seen, but it could have far-reaching implications for neurodegenerative diseases more broadly.